Short vs Long-Term ADT with SRT for Prostate Cancer Recurrence

What is it about?

The URONCOR 06-24 trial is a phase III clinical trial aimed at determining the impact of short-term vs long-term Androgen-Deprivation Therapy (ADT) in combination with Salvage Radiotherapy (SRT) on Distant Metastasis-Free Survival (MFS) in patients with prostate cancer who develop Biochemical Recurrence (BCR) after Radical Prostatectomy (RP). The primary endpoint is 5-year MFS rates in patients with prostate cancer treated with long-vs short-term ADT in combination with SRT. The trial will enroll 534 patients and is estimated to be completed by March 2026. The study is funded by the Instituto de Investigación en Oncología Radioterápica (IRAD).

Featured Image

Why is it important?

This research is important because it aims to determine the optimal duration of androgen-deprivation therapy (ADT) combined with salvage radiotherapy (SRT) in patients with prostate cancer who have biochemical recurrence (BCR) after radical prostatectomy (RP). The study seeks to identify a standard of care consensus for the indications and duration of ADT in this patient population. Key Takeaways: 1. The URONCOR 06-24 trial is a prospective, multicentre, randomised, open-label, phase III clinical trial aiming to determine the impact of short-term (6 months) vs long-term (24 months) ADT in combination with SRT on distant metastasis-free survival (MFS) in patients with prostate cancer with BCR after RP. 2. The primary endpoint is 5-year MFS rates in patients with prostate cancer treated with long-vs short-term ADT in combination with SRT. 3. Secondary objectives include biochemical-relapse free interval, pelvic progression-free survival, time to start of systemic treatment, time to castration resistance, cancer-specific survival, overall survival, acute and late toxicity, and quality of life. 4. The study aims to enrol 534 patients, stratified by risk group and pathological lymph node status. 5. The trial is funded by the Instituto de investigación en Oncología radioterápica (IRAD).